Ronald Muhlenkamp
Muhlenkamp & Co
Ronald Muhlenkamp Bristol-Myers Squibb Company stake
total: 197
Muhlenkamp & Co BMY trades
- Total transactions:
- 35
- New positions:
- 2
- Sold out:
- 2
- Added:
- 19
- Reduced:
- 12
- Held since:
- 2019 Q4
- Held for:
- 16 quarters
- Latest activity:
- 2024 Q2
According to 2026 Q2 report, Ronald Muhlenkamp doesn't hold any Bristol-Myers Squibb Company (BMY) shares. To date, the estimated cost basis is nearly $63.91 for "buy" trades and estimated average "sell" price is $54.24. Muhlenkamp & Co first purchased BMY in 2014 Q1, initially acquiring 212,015 shares. Ronald Muhlenkamp later completely sold out the position and invested in Bristol-Myers Squibb Company again in 2019 Q4. Since the initial investment in Bristol-Myers Squibb Company (BMY), Muhlenkamp & Co has made 34 more transactions.
When did Ronald Muhlenkamp sell Bristol-Myers Squibb Company (BMY)?
Ronald Muhlenkamp sold off the entire Bristol-Myers Squibb Company (BMY) position in 2024 Q2.
When did Ronald Muhlenkamp buy Bristol-Myers Squibb Company (BMY)?
Ronald Muhlenkamp first invested in Bristol-Myers Squibb Company (BMY) in 2014 Q1 at the reported quarter-end price of $51.95 per share.
What's the cost basis of Muhlenkamp & Co's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $63.91 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $63.90
- Weighted AVG sell price:
- $54.24
Ronald Muhlenkamp's historical trades in Bristol-Myers Squibb Company
35 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q2
|
0.00%
|
0
|
$54.23
|
|
-100% (-135,045)
|
-2.13%
|
|
2024 Q1
|
2.13%
|
135,045
|
$54.23
|
$7,323,490
|
+2.49% (+3,285)
|
+0.05%
|
|
2023 Q4
|
2.21%
|
131,760
|
$51.31
|
$6,760,606
|
+1.56% (+2,028)
|
+0.03%
|
|
2023 Q3
|
2.60%
|
129,732
|
$58.04
|
$7,529,645
|
+0.13% (+163)
|
+0%
|
|
2023 Q2
|
2.94%
|
129,569
|
$63.95
|
$8,285,938
|
+0.48% (+619)
|
+0.01%
|
|
2022 Q4
|
3.93%
|
128,950
|
$71.95
|
$9,277,953
|
+0.15% (+197)
|
+0.01%
|
|
2022 Q3
|
4.09%
|
128,753
|
$71.09
|
$9,153,000
|
+0.94% (+1,197)
|
+0.04%
|
|
2022 Q2
|
4.60%
|
127,556
|
$77.00
|
$9,822,000
|
+0.51% (+650)
|
+0.02%
|
|
2022 Q1
|
3.23%
|
126,906
|
$73.03
|
$9,268,000
|
+0.73% (+919)
|
+0.02%
|
|
2021 Q4
|
2.74%
|
125,987
|
$62.35
|
$7,855,000
|
+0.45% (+568)
|
+0.01%
|
|
2021 Q3
|
2.85%
|
$59.17
|
-0.16% (-204)
|
|||
|
2021 Q2
|
3.08%
|
$66.82
|
+0.16% (+204)
|
|||
|
2021 Q1
|
3.20%
|
$68.96
|
+0.22% (+281)
|
|||
|
2020 Q4
|
3.12%
|
$62.03
|
+0.73% (+913)
|
|||
|
2020 Q3
|
3.88%
|
$60.29
|
+0.77% (+952)
|
|||
|
2020 Q2
|
3.88%
|
$58.80
|
+0.04% (+50)
|
|||
|
2019 Q4
|
3.46%
|
$64.19
|
new
|
|||
|
2018 Q2
|
0.00%
|
$63.25
|
-100% (-178,436)
|
|||
|
2018 Q1
|
4.12%
|
$63.25
|
+2.21% (+3,861)
|
|||
|
2017 Q4
|
3.30%
|
$61.28
|
-1.46% (-2,594)
|
|||
|
2017 Q3
|
3.75%
|
$63.74
|
-0.45% (-805)
|
|||
|
2017 Q2
|
3.25%
|
$55.72
|
-0.13% (-227)
|
|||
|
2017 Q1
|
3.14%
|
$54.38
|
-0.42% (-760)
|
|||
|
2016 Q4
|
3.49%
|
$58.44
|
-0.75% (-1,355)
|
|||
|
2016 Q3
|
3.72%
|
$53.92
|
-0.56% (-1,024)
|
|||
|
2016 Q2
|
5.25%
|
$73.55
|
-14.54% (-30,860)
|
|||
|
2016 Q1
|
5.58%
|
$63.88
|
+0.21% (+445)
|
|||
|
2015 Q4
|
4.59%
|
$68.79
|
+0.00% (+5)
|
|||
|
2015 Q3
|
3.85%
|
$59.20
|
+0.06% (+130)
|
|||
|
2015 Q2
|
3.17%
|
$66.54
|
-0.26% (-550)
|
|||
|
2015 Q1
|
2.89%
|
$64.50
|
-0.06% (-120)
|
|||
|
2014 Q4
|
2.53%
|
$59.03
|
-0.09% (-195)
|
|||
|
2014 Q3
|
1.99%
|
$51.18
|
-0.13% (-285)
|
|||
|
2014 Q2
|
1.84%
|
$48.51
|
+0.36% (+755)
|
|||
|
2014 Q1
|
1.95%
|
$51.95
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.